Evidence map›Paper›PMID 36646893›Full record

ArticleCommunications medicine2023

Pathway-guided monitoring of the disease course in bladder cancer with longitudinal urine proteomics.

Luís Botelho Carvalho, José Luis Capelo, Carlos Lodeiro, Rajiv Dhir, Luis Campos Pinheiro, Hugo López-Fernández, Gonçalo Martins, Mariana Medeiros, Fernando Díaz, Hugo Miguel Santos

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 3 countries.

Luís Botelho CarvalhoBIOSCOPE Research Group, LAQV-REQUIMTE, Department of Chemistry, NOVA School of Science and Technology, Universidade NOVA de Lisboa, 2829-516, Caparica, Portugal.ORCID http://orcid.org/0000-0002-3761-8512
José Luis CapeloBIOSCOPE Research Group, LAQV-REQUIMTE, Department of Chemistry, NOVA School of Science and Technology, Universidade NOVA de Lisboa, 2829-516, Caparica, Portugal.ORCID http://orcid.org/0000-0001-6276-8507
Carlos LodeiroBIOSCOPE Research Group, LAQV-REQUIMTE, Department of Chemistry, NOVA School of Science and Technology, Universidade NOVA de Lisboa, 2829-516, Caparica, Portugal.ORCID http://orcid.org/0000-0001-5582-5446
Rajiv DhirDepartment of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Luis Campos PinheiroUrology Department, Central Lisbon Hospital Center, Lisbon, Portugal.
Hugo López-FernándezCINBIO, Universidade de Vigo, Department of Computer Science, ESEI-Escuela Superior de Ingenierı́a Informática, 32004, Ourense, Spain.
Gonçalo MartinsBIOSCOPE Research Group, LAQV-REQUIMTE, Department of Chemistry, NOVA School of Science and Technology, Universidade NOVA de Lisboa, 2829-516, Caparica, Portugal.
Mariana MedeirosUrology Department, Central Lisbon Hospital Center, Lisbon, Portugal.
Fernando DíazDepartment of Computer Science, Universidad de Valladolid, Escuela de Ingeniería Informática, 40005, Segovia, Spain.
Hugo Miguel SantosBIOSCOPE Research Group, LAQV-REQUIMTE, Department of Chemistry, NOVA School of Science and Technology, Universidade NOVA de Lisboa, 2829-516, Caparica, Portugal. hmsantos@fct.unl.pt.ORCID http://orcid.org/0000-0002-6032-8679
Rede de Química e Tecnologia · PTUniversity of Lisbon · PTGalicia Sur Biomedical Foundation · ESUniversidad de Valladolid · ESUniversidade dos Açores · PTUniversity of Pittsburgh Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMonitoring bladder cancer over time requires invasive and costly procedures. Less invasive approaches are required using readily available biological samples such as urine. In this study, we demonstrate a method for longitudinal analysis of the urine proteome to monitor the disease course in patients with bladder cancer.

methodsWe compared the urine proteomes of patients who experienced recurrence and/or progression (n = 13) with those who did not (n = 17). We identified differentially expressed proteins within various pathways related to the hallmarks of cancer. The variation of such pathways during the disease course was determined using our differential personal pathway index (dPPi) calculation, which could indicate disease progression and the need for medical intervention.

resultsSeven hallmark pathways are used to develop the dPPi. We demonstrate that we can successfully longitudinally monitor the disease course in bladder cancer patients through a combination of urine proteomic analysis and the dPPi calculation, over a period of 62 months.

conclusionsUsing the information contained in the patient's urinary proteome, the dPPi reflects the individual's course of bladder cancer, and helps to optimise the use of more invasive procedures such as cystoscopy.

Identifiers

PMID36646893
PMCPMC9842762
OpenAlexW4316500455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.